At AIDS 2016, Researchers Announce Large Clinical Trial Of Experimental HIV Vaccine In South Africa

Agence France-Presse: Early HIV vaccine results lead to major trial: researchers
“Promising results from an early safety trial with a potential HIV vaccine have paved the way for a major new study, researchers announced at the International AIDS Conference in Durban on Tuesday. An 18-month trial with a candidate vaccine dubbed HVTN100 drew on 252 participants at six sites in South Africa, one of the countries hardest-hit by an epidemic that has claimed more than 30 million lives worldwide since the 1980s…” (7/19).

CNN: New HIV vaccine to be trialed in South Africa
“… ‘This [small study] was precautionary to see if the vaccine looks promising,’ said Linda Gail Bekker, deputy director of the Desmond Tutu HIV Centre in Cape Town, South Africa, and president-elect of the International AIDS Society, who is leading the vaccine trials. The vaccine stems from a landmark trial in Thailand in 2009 that was the first to show any protection against HIV, with 31 percent protection against the virus. This was enough to get experts in the field excited after years with no success…” (Senthilingam, 7/19).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.